Condition
    Moderate Evidence
    Effectiveness 3/5

    Ashwagandha for Anxiety

    Standardized ashwagandha root extract (300-600 mg/day) produces meaningful reductions in self-reported anxiety across several small randomised trials, with effects typically appearing within 6-8 weeks.

    Overview

    Ashwagandha has the strongest evidence of any botanical marketed for stress. A 2021 systematic review and meta-analysis of 12 randomized trials found significant reductions in both perceived stress scores and serum cortisol, and the World Federation of Societies of Biological Psychiatry and Canadian Network for Mood and Anxiety Treatments taskforce gave it a provisional recommendation as an adjunct for anxiety — a rare position for a herbal agent. That said, the evidence has a shape worth understanding. The trials are small, mostly 50 to 130 participants, mostly conducted in India, mostly 8 weeks long, and a substantial share are funded by extract manufacturers. Effect sizes vary widely between studies, which usually signals that the true effect is smaller than the headline figures. Read the direction as reliable and the magnitude as optimistic. Ashwagandha is best understood as an adjunct for subclinical stress and mild anxiety in people who have already addressed sleep, exercise and caffeine. It is not a treatment for generalized anxiety disorder, where CBT and SSRI therapy have far larger and better-established effects, and using it to postpone proper care is the main risk it carries.

    Verdict

    Likely effective

    Consistent reductions in perceived stress and cortisol across a dozen small randomized trials, with a provisional taskforce recommendation as an adjunct. Trials are small, short, and often industry-funded.

    How It Works

    The active constituents are withanolides, a family of steroidal lactones, with withaferin A and withanolide A among the most studied. Standardised extracts are typically specified by withanolide content — commonly 5% for root extracts such as KSM-66, or a higher percentage for concentrated preparations like Sensoril, which includes leaf material. The primary proposed mechanism is modulation of the hypothalamic-pituitary-adrenal axis. Trials consistently report reductions in morning serum cortisol of roughly 20-30% relative to placebo, and the effect on subjective stress tracks the cortisol change reasonably well across studies. Animal work suggests this operates partly through reduced hypothalamic corticotropin-releasing hormone signalling rather than adrenal suppression. A second strand is GABAergic. Withanolides show GABA-A receptor mimetic activity in preclinical models, which would account for the calming and sleep-onset effects reported in trials. There is also evidence of effects on serotonergic signalling and on brain-derived neurotrophic factor, though these rest largely on animal data. Unlike a benzodiazepine, ashwagandha does not produce acute sedation at typical doses and does not appear to cause tolerance or withdrawal. The corollary is that it does not work acutely either — the trial effects emerge over 8 weeks, not within an hour.

    Proposed mechanisms

    HPA axis modulation, reduced cortisol output
    GABA-A receptor mimetic activity
    Serotonergic signalling effects
    Increased BDNF expression (preclinical)
    Antioxidant and anti-inflammatory activity
    No tolerance or withdrawal observed

    Dosing & Protocol

    Dosing by preparation

    PreparationTypical doseStandardisationNotes
    KSM-66 root extract300-600 mg daily5% withanolidesMost trialled extract for stress and cortisol. Often split into two doses
    Sensoril root and leaf extract125-250 mg daily10% withanolidesMore concentrated; lower dose. Some report more sedation
    Generic root extract300-600 mg dailyAt least 2.5-5% withanolidesCheck standardisation — unstandardised powder is not comparable
    Whole root powder3-6 g dailyNot standardisedTraditional use. Dose is much higher and content is variable

    Trial durations were typically 8 weeks; a few ran to 12. Almost no controlled safety data exist beyond three months of continuous use.

    How to trial it

    1. 1

      Do the behavioural work first· Weeks 0-2, ongoing

      Regular aerobic exercise, consistent sleep timing and cutting afternoon caffeine outperform ashwagandha. Trialling a supplement on top of an unaddressed lifestyle pattern wastes 8 weeks.

    2. 2

      Record a baseline· Before day 1

      Complete a PSS-10 or GAD-7 before starting. Without a baseline score you will be judging the result on recall, which is unreliable.

    3. 3

      Start at 300 mg· Weeks 1-4

      Use a standardised root extract, 300 mg daily with food. Take it in the morning, or split morning and evening if you find it settling at night.

    4. 4

      Increase if needed· Weeks 4-8

      If tolerated with no change at four weeks, go to 600 mg daily. Most positive trials used 600 mg.

    5. 5

      Reassess at 8 weeks· Week 8

      Repeat the same questionnaire. A meaningful change should be visible on the score, not just in impression.

    6. 6

      Cycle or stop· Week 12

      Given the absence of long-term safety data, take a break after 8-12 weeks. If nothing changed, stop rather than continuing indefinitely.

    Evidence

    What the studies say

    The most influential single trial is Chandrasekhar and colleagues, 2012, which randomized 64 adults with chronic stress to 300 mg of a high-concentration root extract twice daily or placebo for 60 days. The treated group showed a 44% reduction in Perceived Stress Scale scores versus 5.5% on placebo, and a 27.9% reduction in serum cortisol. The effect size is large enough to be treated with some caution, and the study was small. The 2021 systematic review by Akhgarjand and colleagues pooled 12 randomized trials and confirmed significant reductions in both anxiety and cortisol, while noting substantial heterogeneity between studies and high risk of bias in several. A later meta-analysis extending to 15 trials reached similar conclusions. On sleep, a 2021 meta-analysis of five trials found small but statistically significant improvements in sleep quality, with the largest effects in participants who had a formal insomnia diagnosis and at doses of 600 mg or above. The important limitation across all of this is external validity. Most trials were conducted in India in populations with different baseline diets and stress profiles, most were 8 weeks, and manufacturer funding is common. No large independent multi-site trial has been published.

    Evidence at a glance

    Number of randomized trials
    12-15, pooled in several meta-analyses
    Typical sample size
    50-130 participants
    Typical duration
    8 weeks
    Cortisol reduction
    Roughly 20-30% versus placebo
    Guideline status
    Provisional recommendation as an anxiety adjunct (WFSBP/CANMAT taskforce)
    Main limitation
    Small, short, geographically concentrated, frequently industry-funded

    Safety

    Liver injury has been reported

    Case reports of ashwagandha-associated hepatotoxicity have accumulated, generally presenting as cholestatic or mixed liver injury weeks to months into use, and generally resolving on withdrawal. It is rare but real. Stop immediately and seek medical assessment for jaundice, dark urine, pale stools, right upper quadrant pain or unexplained itching. Do not use if you have existing liver disease.

    Do not use if

    Pregnant — traditionally regarded as abortifacient
    Breastfeeding — no safety data
    Existing liver disease
    Autoimmune thyroid disease, without clinician input
    Hormone-sensitive prostate cancer
    Scheduled for surgery within two weeks
    Taking immunosuppressants after transplant

    Thyroid effects and other cautions

    Ashwagandha can raise T3 and T4 and lower TSH. In someone with subclinical hypothyroidism that may be incidental or even mildly beneficial, but in hyperthyroidism or in anyone on levothyroxine it can push levels out of range, and thyroid function should be monitored. There are case reports of thyrotoxicosis. Common and mild side effects are gastrointestinal — nausea, loose stools, abdominal discomfort — and drowsiness, particularly with higher-withanolide leaf-containing extracts. Taking it with food reduces the gastrointestinal effects. Because it may stimulate aspects of immune function, it is generally avoided in people taking immunosuppressants after organ transplant. Its mild sedative properties are a reason to stop two weeks before elective surgery.

    Interactions & Conflicts

    Interactions to plan around

    Interacts withSeverityMechanismAction
    Levothyroxine and other thyroid medication
    moderate
    		Ashwagandha can raise T3 and T4 and suppress TSHMonitor thyroid function; discuss with your prescriber before starting
    Sedatives, benzodiazepines and alcohol
    moderate
    		Additive central depressant effectAvoid combining; be cautious with driving when starting
    Immunosuppressants (tacrolimus, ciclosporin)
    high
    		Possible immune stimulation opposing the drugAvoid in transplant recipients and in immunosuppressed patients
    Antidiabetic medication
    moderate
    		Ashwagandha may lower blood glucoseMonitor glucose more closely; watch for hypoglycaemia
    Antihypertensives
    low
    		Possible additive blood pressure reductionMonitor blood pressure when starting
    Other hepatotoxic agents and alcohol
    moderate
    		Additive risk of liver injuryLimit alcohol; avoid stacking with other supplements associated with hepatotoxicity

    References

    1. Chandrasekhar K et al. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root. Indian J Psychol Med. 2012
    2. Akhgarjand C et al. Does Ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta-analysis. Phytother Res. 2022
    3. Cheah KL et al. Effect of Ashwagandha (Withania somnifera) extract on sleep: a systematic review and meta-analysis. PLoS One. 2021
    4. Sarris J et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: WFSBP and CANMAT taskforce. World J Biol Psychiatry. 2022
    5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury — Ashwagandha. NIDDK

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.